A new medication, Jetrea (ocriplasmin), has been approved by the FDA for VMA (symptomatic vitreomacular adhesion), an eye condition related to aging that can lead to complications and vision loss. When the vitreous gel adheres too strongly to the retina, it can lead to VMT (vitreomacular traction), which may in the long-run affect vision significantly. The patient may eventually develop a range of eye disorders, including macular pucker, macular hole, AMD (age-related macular generation), retinal tears, detachment, and macular edema. Symptomatic VMA is not a disease or a problem in itself, but if left untreated can lead to eye conditions that may result in vision loss, and even total blindness.To see more details visit, www.medicalnewstoday.com